Story perspectives

AstraZeneca, BMS Talk $400B Merger, Face Antitrust Review

8/3/2026

Summary

AstraZeneca &BMS Merge

AstraZeneca Plc and Bristol Myers Squibb Co. are in talks on a $400 billion merger.
The companies value at £196 billion ($263 billion) and $133 billion respectively, which would create the fourth-largest pharma group.
Their combined oncology units, including Opdivo and Imfinzi, generated $4.3 billion in Q2 2026.
The U.S. FTC, UK CMA and European Commission will review the deal for antitrust.
AstraZeneca shares fell over 7 % to £116.46, while BMS shares rose about 1 %.

Summary

AstraZeneca-BMS Merger

The merger would give a single supplier control over oncology biologics, threatening Kenya’s Social Health Insurance Fund because treatments can exceed $100,000 per patient.
Both companies face a patent cliff later this decade, with key blockbuster patents set to expire, prompting the deal to protect future revenue.
The combined R&D budget would outsize rivals such as Pfizer and Novartis, potentially accelerating development of new antibody-drug conjugates and checkpoint inhibitors.

History

Historical Context

At the turn of the millennium, Glaxo Wellcome merged with SmithKline Beecham, creating GlaxoSmithKline—a top-ten global pharma with $42.4 billion revenue in 2025 and a headquarters in London, where it is listed on the London Stock Exchange’s FTSE 100. That consolidation demonstrated how regulators scrutinize mega-mergers, a pattern echoed today as AstraZeneca seeks a $400 billion merger with Bristol Myers Squibb.

1 of 3

AstraZeneca &BMS Merge

AstraZeneca Plc and Bristol Myers Squibb Co. are in talks on a $400 billion merger.
The companies value at £196 billion ($263 billion) and $133 billion respectively, which would create the fourth-largest pharma group.
Their combined oncology units, including Opdivo and Imfinzi, generated $4.3 billion in Q2 2026.
The U.S. FTC, UK CMA and European Commission will review the deal for antitrust.
AstraZeneca shares fell over 7 % to £116.46, while BMS shares rose about 1 %.

1 / 3